Format

Send to

Choose Destination
J Clin Invest. 2018 Oct 1;128(10):4372-4386. doi: 10.1172/JCI97911. Epub 2018 Jul 24.

Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans.

Author information

1
argenx BVBA, Zwijnaarde, Belgium.
2
Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center, College Station, Texas, USA.
3
Department of Biomedical Engineering, Texas A&M University, College Station, Texas, USA.
4
Department of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, Bryan, Texas, USA.

Abstract

BACKGROUND:

Intravenous Ig (IVIg), plasma exchange, and immunoadsorption are frequently used in the management of severe autoimmune diseases mediated by pathogenic IgG autoantibodies. These approaches modulating IgG levels can, however, be associated with some severe adverse reactions and a substantial burden to patients. Targeting the neonatal Fc receptor (FcRn) presents an innovative and potentially more effective, safer, and more convenient alternative for clearing pathogenic IgGs.

METHODS:

A randomized, double-blind, placebo-controlled first-in-human study was conducted in 62 healthy volunteers to explore single and multiple ascending intravenous doses of the FcRn antagonist efgartigimod. The study objectives were to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity. The findings of this study were compared with the pharmacodynamics profile elicited by efgartigimod in cynomolgus monkeys.

RESULTS:

Efgartigimod treatment resulted in a rapid and specific clearance of serum IgG levels in both cynomolgus monkeys and healthy volunteers. In humans, single administration of efgartigimod reduced IgG levels up to 50%, while multiple dosing further lowered IgGs on average by 75% of baseline levels. Approximately 8 weeks following the last administration, IgG levels returned to baseline. Efgartigimod did not alter the homeostasis of albumin or Igs other than IgG, and no serious adverse events related to efgartigimod infusion were observed.

CONCLUSION:

Antagonizing FcRn using efgartigimod is safe and results in a specific, profound, and sustained reduction of serum IgG levels. These results warrant further evaluation of this therapeutic approach in IgG-driven autoimmune diseases.

TRIAL REGISTRATION:

Clinicaltrials.gov NCT03457649.

FUNDING:

argenx BVBA.

KEYWORDS:

Autoimmune diseases; Autoimmunity; Immunoglobulins; Therapeutics

PMID:
30040076
PMCID:
PMC6159959
[Available on 2019-01-01]
DOI:
10.1172/JCI97911
Free full text

Supplemental Content

Full text links

Icon for American Society for Clinical Investigation
Loading ...
Support Center